1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 12
2 Introduction 13
2.1 Peripheral Vascular Stents Overview 13
3 Products under Development 14
3.1 Peripheral Vascular Stents - Pipeline Products by Stage of Development 14
3.2 Peripheral Vascular Stents - Pipeline Products by Segment 15
3.3 Peripheral Vascular Stents - Pipeline Products by Territory 16
3.4 Peripheral Vascular Stents - Pipeline Products by Regulatory Path 17
3.5 Peripheral Vascular Stents - Pipeline Products by Estimated Approval Date 18
3.6 Peripheral Vascular Stents - Ongoing Clinical Trials 19
4 Peripheral Vascular Stents - Pipeline Products under Development by Companies 20
4.1 Peripheral Vascular Stents Companies - Pipeline Products by Stage of Development 20
4.2 Peripheral Vascular Stents - Pipeline Products by Stage of Development 22
5 Peripheral Vascular Stents Companies and Product Overview 25
5.1 3D Biotek LLC Company Overview 25
5.2 480 Biomedical Inc Company Overview 26
5.3 Abbott Vascular Inc. Company Overview 30
5.4 Biotronik SE & Co KG Company Overview 32
5.5 Boston Scientific Corp Company Overview 37
5.6 C. R. Bard Inc Company Overview 43
5.7 Cardiatis SA Company Overview 45
5.8 Cook Medical Inc Company Overview 46
5.9 Cordis Corp Company Overview 58
5.10 Corinnova Inc Company Overview 62
5.11 Cytograft Tissue Engineering Inc Company Overview 63
5.12 Efferent Labs Inc Company Overview 64
5.13 Electroformed Stents Inc Company Overview 65
5.14 Elixir Medical Corp Company Overview 68
5.15 Hexacath Company Overview 70
5.16 InspireMD Inc Company Overview 72
5.17 Intact Vascular, LLC Company Overview 74
5.18 Lifetech Scientific (Shenzhen) Co., Ltd. Company Overview 77
5.19 LimFlow GmbH Company Overview 79
5.20 Medinol Ltd Company Overview 81
5.21 Medtronic plc Company Overview 83
5.22 MicroVention, Inc. Company Overview 85
5.23 Natec Medical Ltd Company Overview 86
5.24 Nexeon MedSystems Inc Company Overview 87
5.25 Nipro Corp Company Overview 89
5.26 Northwestern University Company Overview 91
5.27 NSVascular, Inc. Company Overview 92
5.28 PeriTec Biosciences Ltd Company Overview 94
5.29 Stron Medical Company Overview 96
5.30 Synergy Flow Ltd Company Overview 98
5.31 Taewoong Medical Co.,Ltd. Company Overview 99
5.32 Tepha Inc Company Overview 109
5.33 TissueGen Inc Company Overview 110
5.34 University of Michigan Company Overview 112
5.35 University of Texas Medical Branch at Galveston Company Overview 113
5.36 Vascular Bioresorbable Technologies Company Overview 114
5.37 Vascular Concepts Ltd Company Overview 116
5.38 Veniti Inc Company Overview 119
5.39 Veryan Medical Limited Company Overview 122
5.40 VueKlar Cardiovascular Ltd Company Overview 126
5.41 Xenogenics Corporation Company Overview 129
6 Peripheral Vascular Stents- Recent Developments 132
6.1 Nov 22, 2016: Medtronic Reports Second Quarter Financial Results 132
6.2 Nov 21, 2016: VEITHsymposium 2016: BIOTRONIK Showcases Positive Results for Pulsar-18 Stent in the SFA 134
6.3 Nov 18, 2016: Abbott Labs Prices Public Offering of 4.75% Notes due 2036 for USD1.7 Billion 135
6.4 Nov 16, 2016: Medtronic Releases FY16 Integrated Performance Report 135
6.5 Nov 15, 2016: Final Patient Enrolled for Iliofemoral Venous Stent Study 136
6.6 Nov 15, 2016: LimFlow Receives CE Mark for Purely Percutaneous Critical Limb Ischemia Technology Designed to Restore Perfusion for “No Option” Patients 136
6.7 Nov 15, 2016: CEVA to work with Medtronic for distribution facility construction 137
6.8 Nov 14, 2016: AngioDynamics Prices Public Offering of Shares for USD32 Million 138
6.9 Nov 14, 2016: InspireMD Reports Financial Results for the Third Quarter Ended September 30, 2016 138
6.10 Nov 14, 2016: Neovasc Reports Third Quarter Results for 2016 140
6.11 Nov 09, 2016: AngioDynamics Announces Addition of New Board Members 142
6.12 Oct 31, 2016: FDA Approves TOBA II BTK Pivotal IDE Clinical Study 143
6.13 Oct 27, 2016: CONMED Announces Third Quarter 2016 Financial Results 144
6.14 Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016 145
6.15 Oct 26, 2016: Merit Medical Reports Sales Up 15.3% for the Quarter Ended September 30, 2016 146
6.16 Oct 25, 2016: Edwards Lifesciences Reports Third Quarter Results 147
6.17 Oct 25, 2016: Bard Announces Third Quarter Results 149
6.18 Oct 24, 2016: Boston Scientific announced key Presentations on Eluvia Drug-Eluting Vascular Stent System at Transcatheter Cardiovascular Therapeutics 2016 149
6.19 Oct 20, 2016: Akesys Medical and Elixir Medical Announce First Human Implant of the PRAVA Bioresorbable Scaffold for Peripheral Vascular Disease 150
6.20 Oct 19, 2016: Abbott Reports Third-Quarter 2016 Results 151
6.21 Oct 18, 2016: LimFlow Names Daniel Rose as Chief Executive Officer 153
6.22 Oct 11, 2016: Tepha Enters into Agreement with Metabolix 154
6.23 Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer 154
6.24 Oct 05, 2016: AngioDynamics Reports Fiscal 2017 First Quarter Results 155
6.25 Sep 27, 2016: Boston Scientific Acquires EndoChoice for USD210 Million in Tender Offer 156
6.26 Sep 15, 2016: STENTYS Reports 2016 First-Half Results 156
6.27 Sep 15, 2016: Medtronic Names Mark Ploof Senior Vice President of Global Operations and Business Services 157
6.28 Sep 08, 2016: VENITI Raises USD25 Million in Series D Equity Financing 158
6.29 Sep 07, 2016: GORE VIABAHN Endoprosthesis Marks 20 Years of Proven Performance 158
6.30 Sep 07, 2016: InspireMD Appoints Thomas Kester to Board of Directors 159
6.31 Aug 31, 2016: Cook Medical Names Jean-Marc Creissel Vice President of Operations in Greater China 160
6.32 Aug 25, 2016: Medtronic Reports First Quarter Financial Results 160
6.33 Aug 09, 2016: InspireMD Reports Financial Results for the Second Quarter Ended June 30, 2016 163
6.34 Aug 09, 2016: Neovasc Reports Second Quarter Results for 2016 165
6.35 Aug 03, 2016: EndoChoice Announces Second Quarter 2016 Financial Results 167
6.36 Aug 02, 2016: GORE TIGRIS Vascular Stent Gains FDA Approval for Treatment of Peripheral Artery Disease 169
6.37 Jul 28, 2016: Boston Scientific Announces Results For Second Quarter 2016 170
6.38 Jul 27, 2016: Merit Medical Reports Sales Up 9.4% for the Quarter Ended June 30, 2016 171
6.39 Jul 27, 2016: CONMED Announces Second Quarter 2016 Financial Results 172
6.40 Jul 26, 2016: Merit Medical Announces Appointment of New Director 173
6.41 Jul 26, 2016: Edwards Lifesciences Reports Second Quarter Results 173
6.42 Jul 26, 2016: Bard Announces Second Quarter Results 175
6.43 Jul 25, 2016: AngioDynamics Appoints Michael C. Greiner as New Chief Financial Officer 176
6.44 Jul 21, 2016: Svelte Medical Systems Raises USD4 Million in Venture Financing 176
6.45 Jul 20, 2016: Abbott Reports Second-Quarter 2016 Results 176
6.46 Jul 13, 2016: Boston Scientific Elects Yoshiaki Fujimori to Board of Directors 178
6.47 Jul 13, 2016: AngioDynamics Reports Fiscal 2016 Fourth Quarter and Full Year Results 179
6.48 Jul 12, 2016: STENTYS: 41% Increase in Revenues in the Second Quarter of 2016 180
6.49 Jul 05, 2016: Neovasc Receives NASDAQ Notification Regarding Minimum Bid Requirements 180
6.50 Jul 04, 2016: STENTYS: Appointment of Cardiolovascular Device Veteran as New CEO 181
6.51 Jun 30, 2016: NuVasive Agrees to Settle Patent Litigation With Medtronic 181
6.52 Jun 29, 2016: InspireMD Raises USD14.6 Million in Public Offering of Preferred Stock and Warrants 182
6.53 Jun 28, 2016: GORE VIABAHN Endoprosthesis Found to Provide Superior Patency and Reduced Interventions Versus Balloon Angioplasty Alone for Challenging AV Access Cases 182
6.54 Jun 20, 2016: VENITI Announces 1,000th Patient Treated With VICI VENOUS STENT 183
6.55 Jun 08, 2016: Boston Scientific Announces Restructuring Program to Support Long-Term Growth and Innovation 183
6.56 Jun 06, 2016: Medtronic Outlines Future Growth Vision at Investor Day 184
6.57 May 31, 2016: Medtronic Reports Fourth Quarter and Fiscal Year 2016 Financial Results 184
6.58 May 13, 2016: Boston Scientific Announces Presentation of Eluvia stent system at EuroPCR 2016 187
6.59 May 10, 2016: InspireMD Reports Financial Results for the First Quarter Ended March 31, 2016 187
6.60 May 04, 2016: Positive Twelve-Month Tack Optimized Balloon Angioplasty Below-the-Knee (TOBA-BTK) Results Presented at SCAI 2016 189
6.61 May 02, 2016: A.G. Schneiderman Announces $306 Million National Settlement With Olympus 190
6.62 Apr 29, 2016: Neovasc Reports First Quarter Results for 2016 190
6.63 Apr 21, 2016: VENITI Completes First Use Of VICI VERTO VENOUS STENT, Novel Venous Stent System 193
6.64 Apr 20, 2016: Abbott Reports First-Quarter 2016 Results 193
6.65 Apr 13, 2016: STENTYS Reports 38% Increase in Revenues in First Quarter 2016 196
6.66 Apr 07, 2016: AngioDynamics Reports Fiscal 2016 Third Quarter Results 196
6.67 Apr 04, 2016: AngioDynamics Appoints James C. Clemmer as New President and Chief Executive Officer 197
6.68 Mar 29, 2016: Neovasc Announces Results for the Fourth Quarter and Fiscal Year 2015 198
6.69 Mar 16, 2016: STENTYS Reports 2015 Annual Results 201
6.70 Mar 15, 2016: InspireMD Raises USD0.6 Million in Private Placement of Shares and Warrants 202
6.71 Mar 04, 2016: Palmaz Scientific Announces Chapter 11 Filing; Seeks Prospective Buyers for Its Breakthrough Technology 202
6.72 Feb 22, 2016: Boston Scientific Receives CE Mark For Eluvia Drug-Eluting Vascular Stent And Announces Initiation Of New Clinical Trial 203
6.73 Feb 12, 2016: Stentys Raises USD14.3 Million in Rights Offering of Shares 204
6.74 Feb 08, 2016: STENTYS initiates the Commercialization of the first Self-Expanding Drug-Eluting stent for the Below-The-Knee Indication 205
6.75 Jan 26, 2016: Positive Six-Month Tack Optimized Balloon Angioplasty Below-the-Knee (TOBA-BTK) Results Presented at LINC 2016 205
6.76 Jan 13, 2016: STENTYS Reports 81% Year-over-Year Growth in Fourth-Quarter 2015 Revenues 206
6.77 Jan 07, 2016: AngioDynamics Reports Fiscal 2016 Second Quarter Results 207
7 Appendix 209
7.1 Methodology 209
7.2 About GlobalData 212
7.3 Contact Us 212
7.4 Disclaimer 212

1.1 List of Tables
Table 1: Peripheral Vascular Stents - Pipeline Products by Stage of Development 15
Table 2: Peripheral Vascular Stents - Pipeline Products by Segment 16
Table 3: Peripheral Vascular Stents - Pipeline Products by Territory 17
Table 4: Peripheral Vascular Stents - Pipeline Products by Regulatory Path 18
Table 5: Peripheral Vascular Stents - Pipeline Products by Estimated Approval Date 19
Table 6: Peripheral Vascular Stents - Ongoing Clinical Trials 20
Table 7: Peripheral Vascular Stents Companies - Pipeline Products by Stage of Development 21
Table 8: Peripheral Vascular Stents - Pipeline Products by Stage of Development 23
Table 9: 3D Biotek LLC Pipeline Products & Ongoing Clinical Trials Overview 26
Table 10: Bioresorbable Drug Eluting Peripheral Polymer Stent - Product Status 26
Table 11: Bioresorbable Drug Eluting Peripheral Polymer Stent - Product Description 26
Table 12: 480 Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 27
Table 13: Stanza Bioresorbable Pediatric Scaffold - Product Status 27
Table 14: Stanza Bioresorbable Pediatric Scaffold - Product Description 28
Table 15: Stanza Bioresorbable Self-Expanding Scaffold - Product Status 28
Table 16: Stanza Bioresorbable Self-Expanding Scaffold - Product Description 29
Table 17: 480 Biomedical Inc - Ongoing Clinical Trials Overview 30
Table 18: Stanza Bioresorbable Self-Expanding Scaffold - An Evaluation of the 480 Biomedical STANZA Drug-Eluting Resorbable Scaffold (DRS) System in the Treatment of de Novo SFA Lesions 30
Table 19: Abbott Vascular Inc. Pipeline Products & Ongoing Clinical Trials Overview 31
Table 20: ESPRIT Bioresorbable Vascular Scaffold - Product Status 31
Table 21: ESPRIT Bioresorbable Vascular Scaffold - Product Description 32
Table 22: Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview 33
Table 23: Astron Pulsar Self Expanding Peripheral Stent - Product Status 33
Table 24: Astron Pulsar Self Expanding Peripheral Stent - Product Description 34
Table 25: Pulsar-18 Self Expanding Stent - Product Status 34
Table 26: Pulsar-18 Self Expanding Stent - Product Description 35
Table 27: Biotronik SE & Co KG - Ongoing Clinical Trials Overview 35
Table 28: Astron Pulsar Self Expanding Peripheral Stent - The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar-18 Stents (BIOFLEX-I Europe) 36
Table 29: Pulsar-18 Self Expanding Stent - BIOFLEX PEACE All-comers Trial 37
Table 30: Pulsar-18 Self Expanding Stent - Physician-Initiated Trial Investigating the Efficacy of Endovascular Treatment of Femoropopliteal Arterial Stenotic Disease with the Biotronik Passeo-18 Lux Drug Releasing Balloon and the Biotronik Pulsar-18 Stent (Comparing with 4EVER Trial Results) (BIOLUX 4EVER) 37
Table 31: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 38
Table 32: Cobalt-Chromium Iliac Balloon Expandable Stent - Product Status 38
Table 33: Cobalt-Chromium Iliac Balloon Expandable Stent - Product Description 39
Table 34: Eluvia Drug-Eluting Vascular Stent System - Product Status 39
Table 35: Eluvia Drug-Eluting Vascular Stent System - Product Description 39
Table 36: Gallbladder Drainage System - Product Status 40
Table 37: Gallbladder Drainage System - Product Description 40
Table 38: Wallstent RP Endoprosthesis - Venous Outflow Obstruction - Product Status 40
Table 39: Wallstent RP Endoprosthesis - Venous Outflow Obstruction - Product Description 41
Table 40: Boston Scientific Corp - Ongoing Clinical Trials Overview 41
Table 41: Eluvia Drug-Eluting Vascular Stent System - A Randomized Trial Comparing the ELUVIA Drug-eluting Stent Versus Bare Metal Self-expanding Nitinol Stents in the Treatment of Superficial Femoral and/or Proximal Popliteal Arteries 42
Table 42: Eluvia Drug-Eluting Vascular Stent System - A Randomized Trial Comparing the ELUVIA Drug-eluting Stent Versus Zilver PTX Stent for Treatment of Superficial Femoral and/or Proximal Popliteal Arteries 42
Table 43: Eluvia Drug-Eluting Vascular Stent System - Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project with Boston Scientific's Innova Drug Eluting Stent 43
Table 44: Wallstent RP Endoprosthesis - Venous Outflow Obstruction - Sinai Vein Stent Registry 43
Table 45: C. R. Bard Inc Pipeline Products & Ongoing Clinical Trials Overview 44
Table 46: VENOVO Venous Stent - Product Status 44
Table 47: VENOVO Venous Stent - Product Description 45
Table 48: Cardiatis SA Pipeline Products & Ongoing Clinical Trials Overview 46
Table 49: Cardiatis FluidSmart 3D Stent - Product Status 46
Table 50: Cardiatis FluidSmart 3D Stent - Product Description 46
Table 51: Cook Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 47
Table 52: Evolution Biliary Stent System-Partially Covered - Product Status 47
Table 53: Evolution Biliary Stent System-Partially Covered - Product Description 48
Table 54: Evolution Esophageal Stent System-Fully Covered - Product Status 48
Table 55: Evolution Esophageal Stent System-Fully Covered - Product Description 48
Table 56: Zenith Connection Endovascular Covered Stent - Product Status 49
Table 57: Zenith Connection Endovascular Covered Stent - Product Description 49
Table 58: Zenith Helical Branch Iliac Endovascular Graft - Product Status 49
Table 59: Zenith Helical Branch Iliac Endovascular Graft - Product Description 50
Table 60: ZILVER PTX Drug Eluting Peripheral Stent - Product Status 50
Table 61: ZILVER PTX Drug Eluting Peripheral Stent - Product Description 51
Table 62: Zilver Vena Venous Self-Expanding Stent - Product Status 51
Table 63: Zilver Vena Venous Self-Expanding Stent - Product Description 52
Table 64: Cook Medical Inc - Ongoing Clinical Trials Overview 53
Table 65: ZILVER PTX Drug Eluting Peripheral Stent - A Randomized Trial Comparing the ELUVIA Drug-eluting Stent Versus Zilver PTX Stent for Treatment of Superficial Femoral and/or Proximal Popliteal Arteries 54
Table 66: ZILVER PTX Drug Eluting Peripheral Stent - Bare Metal Stent Versus Paclitaxel Eluting Stent in the Setting of Primary Stenting of Intermediate Length Femoropopliteal Lesions 54
Table 67: ZILVER PTX Drug Eluting Peripheral Stent - Comparison of the Primary Long Versus Short Coverage with Drug-Eluting Stents for Long Femoropopliteal Artery Disease (PARADE II): Investigator-initiated Clinical Study 54
Table 68: ZILVER PTX Drug Eluting Peripheral Stent - Drug Eluting Stent for the Management of Peripheral Arterial Disease of the SFA (DESPERADO-SFA Study) 55
Table 69: ZILVER PTX Drug Eluting Peripheral Stent - Evaluation of the Zilver PTX Drug-eluting Peripheral Stent for Treatment of Lesions of the Above-the-knee Femoropopliteal Artery 55
Table 70: ZILVER PTX Drug Eluting Peripheral Stent - Paclitaxel-coated Peripheral Stents Used in the Treatment of Femoropopliteal Stenoses 55
Table 71: ZILVER PTX Drug Eluting Peripheral Stent - The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery for the Treatment The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery of Femoropopliteal TASC C&D Lesions (ZILVERPASS) 56
Table 72: ZILVER PTX Drug Eluting Peripheral Stent - Zilver PTX Drug-eluting Peripheral Stent Post-approval Study 56
Table 73: ZILVER PTX Drug Eluting Peripheral Stent - Zilver PTX Post-market Surveillance Study of Paclitaxel-eluting Stents for Treating Femoropopliteal Artery Disease in Japan 57
Table 74: Zilver Vena Venous Self-Expanding Stent - Evaluation of the Zilver Vena Venous Stent in the Treatment of Symptomatic Iliofemoral Venous Outflow Obstruction 57
Table 75: Evolution Esophageal Stent System-Fully Covered - Clinical Investigation to Evaluate Removal of the Evolution Esophageal Stent - Fully Covered 58
Table 76: Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview 59
Table 77: FlexStent Femoropopliteal Self Expanding Stent System - SFA - Product Status 59
Table 78: FlexStent Femoropopliteal Self Expanding Stent System - SFA - Product Description 60
Table 79: FlexStent Self Expanding Below-The-Knee Venous Stent System - Product Status 60
Table 80: FlexStent Self Expanding Below-The-Knee Venous Stent System - Product Description 60
Table 81: FlexStent Self Expanding Venous Stent System - Product Status 61
Table 82: FlexStent Self Expanding Venous Stent System - Product Description 61
Table 83: Tibial SE FlexStent - Product Status 61
Table 84: Tibial SE FlexStent - Product Description 62
Table 85: Cordis Corp - Ongoing Clinical Trials Overview 62
Table 86: FlexStent Femoropopliteal Self Expanding Stent System - SFA - Evaluation of Safety and Efficacy of the FlexStent Femoropopliteal Self-expanding Stent System Study 62
Table 87: Corinnova Inc Pipeline Products & Ongoing Clinical Trials Overview 63
Table 88: Hybrid Dynamic Stent - Product Status 63
Table 89: Hybrid Dynamic Stent - Product Description 63
Table 90: Cytograft Tissue Engineering Inc Pipeline Products & Ongoing Clinical Trials Overview 64
Table 91: LifeJacket Stent Graft - Peripheral - Product Status 64
Table 92: LifeJacket Stent Graft - Peripheral - Product Description 64
Table 93: Efferent Labs Inc Pipeline Products & Ongoing Clinical Trials Overview 65
Table 94: RTI-LICD Plexisense - Product Status 65
Table 95: RTI-LICD Plexisense - Product Description 65
Table 96: Electroformed Stents Inc Pipeline Products & Ongoing Clinical Trials Overview 66
Table 97: Helical Stent - Product Status 66
Table 98: Helical Stent - Product Description 66
Table 99: Patch Stent - Product Status 67
Table 100: Patch Stent - Product Description 67
Table 101: Pleated Stent - Product Status 67
Table 102: Pleated Stent - Product Description 68
Table 103: Elixir Medical Corp Pipeline Products & Ongoing Clinical Trials Overview 69
Table 104: PRAVA Bioresorbable Scaffold - Product Status 69
Table 105: PRAVA Bioresorbable Scaffold - Product Description 70
Table 106: Elixir Medical Corp - Ongoing Clinical Trials Overview 70
Table 107: PRAVA Bioresorbable Scaffold - Drug Eluting Scaffold with an Absorbable Platform for Primary Lower Extremity Arterial Revascularization (DESappear Study) 70
Table 108: Hexacath Pipeline Products & Ongoing Clinical Trials Overview 71
Table 109: HELIOS LD Peripheral Balloon Expandable Bio Active Stent - Product Status 71
Table 110: HELIOS LD Peripheral Balloon Expandable Bio Active Stent - Product Description 72
Table 111: InspireMD Inc Pipeline Products & Ongoing Clinical Trials Overview 73
Table 112: PVGuard Peripheral - Product Status 73
Table 113: PVGuard Peripheral - Product Description 74
Table 114: Intact Vascular, LLC Pipeline Products & Ongoing Clinical Trials Overview 75
Table 115: Tack Endovascular System - BTK - Product Status 75
Table 116: Tack Endovascular System - BTK - Product Description 75
Table 117: Intact Vascular, LLC - Ongoing Clinical Trials Overview 76
Table 118: Tack Endovascular System - BTK - Prospective, Multicenter Tack Optimized Balloon Angioplasty below the Knee (TOBA - BTK) Study for Infrapopliteal Arteries Using the Tack-it Endovascular System 76
Table 119: Tack Endovascular System - BTK - Tack Optimized Balloon Angioplasty Study for the below the Knee Arteries Using the Tack Endovascular System 77
Table 120: Lifetech Scientific (Shenzhen) Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 78
Table 121: Peripheral Bare Stent - Product Status 78
Table 122: Peripheral Bare Stent - Product Description 78
Table 123: Peripheral Cover Stent - Product Status 79
Table 124: Peripheral Cover Stent - Product Description 79
Table 125: LimFlow GmbH Pipeline Products & Ongoing Clinical Trials Overview 80
Table 126: LimFlow Stent Graft System - Product Status 80
Table 127: LimFlow Stent Graft System - Product Description 81
Table 128: Medinol Ltd Pipeline Products & Ongoing Clinical Trials Overview 82
Table 129: ChampioNIR - Product Status 82
Table 130: ChampioNIR - Product Description 83
Table 131: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 84
Table 132: Maris - Product Status 84
Table 133: Maris - Product Description 85
Table 134: MicroVention, Inc. Pipeline Products & Ongoing Clinical Trials Overview 86
Table 135: CASPER Carotid Stent - Product Status 86
Table 136: CASPER Carotid Stent - Product Description 86
Table 137: Natec Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview 87
Table 138: Marina - Product Status 87
Table 139: Marina - Product Description 87
Table 140: Nexeon MedSystems Inc Pipeline Products & Ongoing Clinical Trials Overview 88
Table 141: CITATION Peripheral Stent System - Product Status 88
Table 142: CITATION Peripheral Stent System - Product Description 89
Table 143: Nipro Corp Pipeline Products & Ongoing Clinical Trials Overview 90
Table 144: Peripheral Stent - Product Status 90
Table 145: Peripheral Stent - Product Description 91

1.2 List of Figures
Figure 1: Peripheral Vascular Stents - Pipeline Products by Stage of Development 15
Figure 2: Peripheral Vascular Stents - Pipeline Products by Segment 16
Figure 3: Peripheral Vascular Stents - Pipeline Products by Territory 17
Figure 4: Peripheral Vascular Stents - Pipeline Products by Regulatory Path 18
Figure 5: Peripheral Vascular Stents - Pipeline Products by Estimated Approval Date 19
Figure 6: Peripheral Vascular Stents - Ongoing Clinical Trials 20